Drug, across the briefings

Rituximab across 8 cancers

Rituximab appears in 8 of the briefings; its FDA label names 4 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Burkitt lymphoma	label names disease	on MS4A1	100	9
Chronic lymphocytic leukemia	label names disease	on MS4A1	163	25
Diffuse large B-cell lymphoma	label names disease	on MS4A1	165	52
Follicular lymphoma	label names disease	on MS4A1	166	27
Hodgkin lymphoma		on MS4A1	34	2
Mantle cell lymphoma		on MS4A1	188	43
Marginal zone lymphoma		on MS4A1	183	46
Waldenström macroglobulinaemia		on MS4A1	16	4

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.